Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DAYSEE vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DAYSEE (estradiol/norethindrone acetate) is a combination hormonal contraceptive that suppresses gonadotropins (FSH and LH) via negative feedback of estrogen and progestin, thereby inhibiting ovulation. Norethindrone also increases cervical mucus viscosity and induces endometrial atrophy.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
FDA-approved: Prevention of pregnancy in women who elect to use an oral contraceptive.,Off-label: Treatment of dysmenorrhea, menstrual cycle regulation, and emergency contraception (off-label use of extended-cycle regimen).
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One active tablet (norgestimate 0.18 mg/ethinyl estradiol 0.025 mg) orally once daily for 21 days, followed by 7 days of placebo. Each cycle: 7 days placebo, then 21 days active.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Terminal elimination half-life is approximately 24 hours (range 18-36 hours), supporting once-daily dosing for steady state within 5 days.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Estradiol is metabolized primarily via hydroxylation (CYP1A2, CYP3A4) and conjugation to glucuronides and sulfates. Norethindrone is metabolized via reduction and conjugation (CYP3A4).
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Renal 70% (metabolites), biliary/fecal 30% (parent drug and metabolites). No active drug excreted unchanged.
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
99% bound to albumin (secondary to alpha-1-acid glycoprotein).
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
10-15 L/kg (large distribution into tissues, including pancreas and liver).
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral: 75% (high; food reduces rate but not extent).
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No specific dose adjustment provided. Use with caution in patients with renal impairment; monitor for fluid retention and hypertension.
No data available for fictional drug ALYACEN 777.
Contraindicated in patients with impaired liver function or active liver disease. No specific dose adjustment recommended.
No data available for fictional drug ALYACEN 777.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults.
No data available for fictional drug ALYACEN 777.
Not indicated for postmenopausal women; no relevant use in geriatric population.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives. This risk increases with age (>35 years) and with the number of cigarettes smoked. Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Thrombotic disorders: venous thromboembolism, arterial thromboembolism (e.g., stroke, MI), especially in smokers ≥35 years.,Hepatic disease: discontinue if jaundice occurs; may cause cholestatic jaundice.,Hypertension: monitor blood pressure; discontinue if significant hypertension develops.,Gallbladder disease: increased risk of gallstones.,Carbohydrate/lipid metabolism: monitor in women with diabetes or hypertriglyceridemia.,Headache: evaluate if new or worsening migraine; discontinue if neurological signs.,Uterine bleeding: irregular bleeding may occur; rule out pregnancy.,Depression: monitor; discontinue if severe.,Hereditary angioedema: may exacerbate.,Ocular effects: discontinue if vision loss or proptosis.
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Known or suspected pregnancy.,Current or history of thrombophlebitis or venous thromboembolic disorders.,Cerebrovascular or coronary artery disease.,Known or suspected breast carcinoma.,Carcinoma of the endometrium or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding.,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use.,Hepatic adenoma or carcinoma, or active liver disease.,Tobacco use in women ≥35 years.
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
No specific food restrictions. Grapefruit juice may increase ethinyl estradiol levels; avoid large amounts. Consistent consumption of St. John's wort, certain antiepileptics (e.g., phenytoin), and rifampin can reduce contraceptive efficacy.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
Daysee (progestin-only pill) has a low teratogenic risk. First trimester: no increased risk of major malformations. Second and third trimesters: no known adverse fetal effects. No association with congenital anomalies.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Compatible with breastfeeding. Progestin-only pills do not suppress lactation. Levonorgestrel is excreted in breast milk in small amounts; estimated infant dose <1% of maternal weight-adjusted dose. M/P ratio not available.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
No dose adjustment is indicated; Daysee is contraindicated during pregnancy. Pregnancy should be ruled out before initiation. No pharmacokinetic changes require dose alteration.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
Daysee (ethinyl estradiol/levonorgestrel) is a combined oral contraceptive (COC) with a 91-day extended cycle regimen (84 active pills, 7 placebo). It reduces the frequency of withdrawal bleeds to 4 per year. Efficacy may be reduced if active pills are missed within the first 7 days of a new cycle. Use backup contraception if vomiting or diarrhea occurs within 3-4 hours of taking a pill.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one pill daily at the same time; missing pills increases pregnancy risk.,You will have fewer periods (about 4 per year) while on Daysee.,Use a backup method (e.g., condoms) if you miss a pill or have severe GI upset.,Do not smoke while on this medication; smoking increases risk of serious cardiovascular side effects.,Inform your doctor if you experience severe headaches, chest pain, or leg swelling.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DAYSEE vs ALYACEN 777, answered by our medical review team.
DAYSEE is a Oral Contraceptive that works by DAYSEE (estradiol/norethindrone acetate) is a combination hormonal contraceptive that suppresses gonadotropins (FSH and LH) via negative feedback of estrogen and progestin, thereby inhibiting ovulation. Norethindrone also increases cervical mucus viscosity and induces endometrial atrophy.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DAYSEE and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DAYSEE is: One active tablet (norgestimate 0.18 mg/ethinyl estradiol 0.025 mg) orally once daily for 21 days, followed by 7 days of placebo. Each cycle: 7 days placebo, then 21 days active.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DAYSEE and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DAYSEE is classified as Category C. Daysee (progestin-only pill) has a low teratogenic risk. First trimester: no increased risk of major malformations. Second and third trimesters: no known adverse fetal effects. No . ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.